GSK pushes new frontiers with $50m bioelectronics medicines punt
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is seeking to blur the lines between man and machine, launching a new $50m venture capital fund dedicated to investing in "bioelectronic medicines," an emerging generation of neuromodulation technologies designed to treat diseases ranging from autoimmune and inflammatory conditions to respiratory disorders.